8-Aminoquinolines: Future role as antiprotozoal drugs

Current Opinion in Infectious Diseases

Volumn 19, Issue 6, 2006, Pages 623-631

  Tekwani, Babu L ^a   Walker, Larry A ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

8 aminoquinoline; Antiprotozoal; Chagas' disease; Leishmaniasis; Malaria

Indexed keywords

8 AMINOQUINOLINE DERIVATIVE; ANTIPROTOZOAL AGENT; BULAQUINE; PAMAQUINE; PENTAQUINE; PRIMAQUINE; SITAMAQUINE; TAFENOQUINE; UNCLASSIFIED DRUG;

CHAGAS DISEASE; DRUG EFFICACY; HUMAN; INFECTION; LEISHMANIASIS; MALARIA; PNEUMOCYSTIS PNEUMONIA; PROTOZOAL INFECTION; REVIEW; STEREOCHEMISTRY; VISCERAL LEISHMANIASIS;

AMINOQUINOLINES; ANIMALS; ANTIPROTOZOAL AGENTS; HUMANS; LEISHMANIA; PROTOZOAN INFECTIONS; TRYPANOSOMA;

EID: 33750512152     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328010b848     Document Type: Review

References (90)

1. Dupouy-Camet J. New drugs for the treatment of human parasitic protozoa. Parasitologia 2004; 46:81-84.
2. Frantz S. PPPs succeeding in tackling neglected diseases. Nat Rev Drug Discov 2005; 4:796-797.
3. Linares GE, Ravaschino EL, Rodriguez JB. Progresses in the field of drug design to combat tropical protozoan parasitic diseases. Curr Med Chem 2006; 13:335-360. This is a useful review on new drugs for treatment of protozoan diseases.
4. Gelb MH, Hol WG. Parasitology drugs to combat tropical protozoan parasites. Science 2002; 297:343-344.
5. Kissinger JC. A tale of three genomes: the kinetoplastids have arrived. Trends Parasitol 2006; 22:240-243.
6. Biot C, Chibale K. Novel approaches to antimalarial drug discovery. Infect Disord Drug Targets 2006; 6:173-204. Target-based new antimalarial drug discovery with use of genome data.
7. Werbovetz K. Diamidines as antitrypanosomal, antileishmanial and antimalarial agents. Curr Opin Investig Drugs 2006; 7:147-157.
8. Carson P. 8-Aminoquinolines. In Antimalarial drugs II, (Peters W, Richards WHG, editors) New York: Springer Verlag; 1984. pp 83-121.
9. Greenwood D. Conflicts of interest; the genesis of synthetic antimalarial agents in peace and war. J Antimicrob Chemother 1995; 36:857-872.
10. White NJ. Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet 1985; 10:187-215.
11. Coleman MD, Coleman NA. Drug-induced methaemoglobinaemia: treatment issues. Drug Saf 1996; 14:394-405.
12. Milhous WK. Development of new drugs for chemoprophylaxis of malaria. Med Trop (Mars) 2001; 61:48-50.
13. Peters W. The evolution of tafenoquine-antimalarial for a new millennium. J Roy Soc Med 1999; 345-352.
14. Yeates C. Sitamaquine. Curr Opin Investig Drugs 2002; 3:1446-1452.
15. Ram P, Prasad BA, Patil TH, et al. Use of primaquine derivatives for the treatment of malaria. European Patent Application 2000; EP 1 055 427 A1.
16. Gogtay NJ, Kamtekar KD, Dalvi SS, et al. A randomized, parallel study of the safety and efficacy of 45mg primaquine versus 75 mg bulaquine as gametocytocidal agents in adults with blood schizonticide-responsive uncomplicated falciparum malaria. BMC Infect Dis 2006; 6:1-4. Clinical use establishes superiority of bulaquine over primaquine as a gametocytocidal agent.
17. Bhat BK, Seth M, Bhaduri AP. Recent developments in 8-aminoquinoline antimalarials. Prog Drug Res 1984; 28:197-231.
18. Brueckner RP, Ohart C, Baird JK, et al. 8-Amnioquinolines. In: Rosenthal PJ, editor. Antimalarial chemotherapy, mechanism of action, resistance and new directions in drug discovery. New Jersey: Humana Press; 2001. pp. 123-151.
19. Nodiff EA, Chatterji S, Msallam HA. Antimalarial activity of the 8-aminoquinolines. Prog Drug Res 1991; 28:1-39.
20. Schmidt LH. Relationships between chemical structures of 8-aminoquinolines and their capability for radical cure of infections with Plasmodium cynomolgi in rhesus monkeys. Antimicrob Agents Chemother 1983; 24:615-652.
21. Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis 2004; 39:1336-1345.
22. Baird JK, Rieckmann KH. Can primaquine therapy for vivax malaria be improved. Trends Parasitol 2003; 19:115-120.
23. Bray PG, Deed S, Fox E, et al. Primaquine synergises the activity of chloroquine against chloroquine resistant Plasmodium falciparum. Biochem Pharmacol 2005; 70:1158-1166. This article reports the synergy between primaquine and chloroquine, using a molecular approach.
24. Peters W, Robinson BL, Milhous WK. Chemotherapy of rodent malaria, studies on a new 8-aminoquinoline antimalarial, WR 238 605. Ann Trop Med Parasitol 1993; 87:547-552.
25. Pukrittayakamee S, Vanijanonta S, Chantra A, et al. Blood stage antimalarial activity antimalarial efficacy of primaquine in Plasmodium vivax malaria. J Infect Dis 1994; 169:932-935.
26. Baird JK, Basri H, Subianto B, et al. Treatment of chloroquine resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Infect Dis 1995; 171:1678-1682.
27. Obaldia N, Rossan RN, Cooper RD, et al. WR 238 605, chloroquine and their combinations as blood schizonticides against a chloroquine-resistant strain of Plasmodium vivax in Aotus monkeys. Am J Trop Med Hyg 1997; 56:508-510.
28. Ramharter M, Noedl H, Thimasarn K, et al. In vitro activity of tafenoquine alone and combination with artemisinin against Plasmodium falciparum. Am J Trop Med Hyg 2002; 67:39-43.
29. Puri SK, Dutta GP. Blood schizontocidal activity of WR238605 (tafenoquine) against Plasmodium cynomolgi and Plasmodium fragile infections in rhesus monkeys. Acta Trop 2003; 86:35-40.
30. LaMontagne MP, Blumbergs P, Strube RE. Antimalarials 14 5-(aryloxy)-4-methylprimaquine analogues. A highly effective series of blood and tissue schizontocidal agents. J Med Chem 1982; 25:1094-1097.
31. McChesney J, Nanayakkara DN, Bartlett M, et al. 8-Aminoquinolines. US Patent 2002. US 6,376,511 B2.
32. Jain M, Vangapandu S, Sachdeva S, et al. Discovery of a bulky 2-tert-butyl group containing primaquine analogue that exhibits potent blood-schizontocidal antimalarial activities and complete elimination of methemoglobin toxicity. J Med Chem 2004; 47:285-287.
33. Vangapandu S, Sachdeva S, Jain M, et al. 8-Aminoquinolines conjugated with amino acids are exhibiting potent blood-schizontocidal antimalarial activities. Bioorg Med Chem 2004; 12:239-247.
34. Vangapandu S, Sachdeva S, Jain M, et al. 8-Quinolamines and their prodrug conjugates as potent blood schizontocidal agents. Bioorg Med Chem 2003; 11:4557-4568.
35. Jain R, Jain M, Singh PP, et al. Process for preparation of rings-substituted 8-aminoquinoline analogs as antimalarial agents. US Patent 2005. US 6,979,740 B2.
36. Jain M, Khan SI, Tekwani BL, et al. Synthesis, antimalarial, antileishmanial and antimicrobial activities of some 8-aminoquinoline analogues. Bioorg Med Chem 2005; 13:4458-4466. This paper discusses novel 8-aminoquinolines with blood schizontocidal, antimalarial and antileishmanial activity.
37. Tracy TS. Stereochemistry in pharmacotherapy: when mirror images are not identical. Ann Pharmacother 1995; 29:161-165.
38. Brocks DR, Mehvar R. Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs. Clin Pharmacokinet 2003; 42:1359-1382.
39. Ward SA, Mihaly GW, Nicholl DD, et al. The pharmacokinetics of (+) - and (-)-primaquine in the isolated perfused rat liver preparation. Biochem Pharmacol 1987; 36:2238-2239.
40. Agarwal S, Gupta UR, Gupta RC, et al. Susceptibility of glucose-6-phosphate dehydrogenase deficient red cells to primaquine enantiomers and two putative metabolites-I. Biochem Pharmacol 1988; 37:4605-4609.
41. Schmidt LH, Alexander S, Allen L, Rasco J. Comparison of the curative antimalarial activities and toxicities of primaquine and its d and l isomers. Antimicrob Agents Chemother 1977; 12:51-60.
42. Baker JK, McChesney JD. Differential metabolism of the enantiomers of primaquine. J Pharm Sci 1988; 77:380-382.
43. Baker JK, Clark AM, Hufford CD. High performance liquid chromatographic separation of the enantiomers and diastereomers of primaquine and its metabolites. J Liq Chromatog 1986; 9:493-509.
44. Berman J. Clinical status of the agents being developed for leishmaniasis. Expert Opin Investig Drugs 2005; 14:1337-1346.
45. Croft SL, Seifert K, Yardley V. Current scenario of drug development for leishmaniasis. Indian J Med Res 2006; 123:399-410. This is a useful review on new drug development against leishmaniasis.
46. Sunder S, Chatterjee M. Visceral leishmaniasis-current therapeutic modalities. Indian J Med Res 2006; 123:345-352.
47. Sangruala H, Sharma KK, Rijal S, et al. Orally effective drugs for kala-azar (Visceral leishmaniasis): focus on miltefosine and sitamaquine. J Assoc Phys India 2003; 686-690.
48. Neal RA. Chemotherapy of cutaneous leishmaniasis: Leishmania tropica infections in mice. Ann Trop Med Parasitol 1964; 58:420-430.
49. Gasper R, Opperodos FR, Preat V, et al. Drug targeting with polyalkylcyanoacrylate nanoparticles: in vitro activity of primaquine-loaded nanoparticles against Leishmania donovani. Ann Trop Med Parasitol 1992; 86:41-49.
50. Rodrigues JM, Croft SL, Fessi H, et al. The activity and ultrastructural localization of primaquine-loaded pol(d,l-lactide) nanoparticles in Leishmania donovani infected mice. Trop Med Parasitol 1994; 45:223-228.
51. Shetty RV, Blanton CD. Synthesis of 2-sustituted primaquine analogues as potential antimalarials. J Med Chem 1978; 21:995-998.
52. LaMontagne MP, Dagli D, Khan MS, et al. Analogues of 8-[[6- (diethylaminohexyl] amino]-6-methoxy-4-methylquinoline as candidate antileishmanial agents. J Med Chem 1980; 23:981-985.
53. Berman JD, Lee LS. Activity of 8-aminoquinolines against Leishmania tropica within human macrophages. Am J Trop Med Hyg 1983; 32:753-759.
54. Neal RA, Croft SL, Nelson DJ. Antileishmanial effect of allopurinol ribonucleoside and the related compounds, allopurinol, thiopurinol, thiopurinol ribonucleoside, and of formycin B, sinefungin and the lepidine WR6026. Trans R Soc Trop Med Hyg 1985; 79:122-128.
55. Sherwood JA, Gachihi GS, Muigai RK, et al. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clin Infect Dis 1994; 19:1034-1039.
56. Dietze R, Carvalho SF, Valli LC, et al. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am J Trop Med Hyg 2001; 65:685-689.
57. Wasunna MK, Rashid JR, Mbui J, et al. A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya. Am J Trop Med Hyg 2005; 73:871-876. This paper reports on the usefulness of sitamaquine in treatment of leishmaniasis.
58. ••], this reports on the usefulness of sitamaquine in treatment of leishmaniasis.
59. Garnier T, Brown MB, Lawrence MJ, et al. In vitro and in vivo studies on a topical formulation of sitamaquine dihydrochloride for cutaneous leishmaniasis. J Pharm Pharmacol 2006; 58:1043-1054. This article is about the usefulness of sitamaquine against cutaneous leishmaniasis.
60. Langreth SG, Berman JD, Riordan GP, et al. Fine-structural alterations in Leishmania tropica within human macrophages exposed to antileishmanial drugs in vitro. J Protozool 1983; 30:555-561.
61. Vercesi AE, Rodrigues CO, Catisti R, et al. Presence of a Na(+)/H(+) exchanger in acidocalcisomes of Leishmania donovani and their alkalization by antileishmanial drugs. FEBS Lett 2000; 472:203-206.
62. Vercesi AE, Docampo R. Ca2+ transport by digitonin permeabilized Leishmania donovani: effects of Ca2+, pentamidine and WR6026 on mitochondrial membrane potential in situ. Biochem J 1992; 284:463-467.
63. Duenas-Romero AM, Loiseau PM, Saint-Pirre-Chazlet M. Interaction of sitamaquine with membrane lipids of Leishmania donovani promastigotes. Biochemica Biophysica Acta. 2006 [epub ahead of print]. This explains the mechanism of action of sitamaquine on Leishmania parasites.
64. Barrett MP, Burchmore RJ, Stich A, et al. The tryparosomiases. Lancet 2003; 362:1469-1480.
65. Steverdind D, Tyler KM. Novel antitrypanosomal agents. Expert Opin Investig Drugs 2005; 14:939-955.
66. Kinnamon KE, Poon BT, Hanson WL, et al. Primaquine analogues that are potent anti-Trypanosoma cruzi agents in a mouse model. Ann Trop Med Parasitol 1996; 90:467-474.
67. McCabe RE. Primaquine is lethal for intracellular but not extracellular Trypanosoma cruzi. J Parasitol 1988; 74:748-753.
68. Globe FC. Activity of certain 6-methoxy-8-aminoquinolines against Trypanosoma cruzi. Antibiotics Chemother 1952; 2:265-270.
69. Beveridge E, Caldwell IC, Latter VS, et al. The activity against Trypanosoma cruzi and cutaneous leishmaniasis, and toxicity, of moxipraquine. Trans R Soc Trop Med Hyg 1980; 74:43-51.
70. Chung MC, Goncalves MF, Colli W, et al. Synthesis and in vitro evaluation of potential antichagasic dipeptide prodrugs of primaquine. J Pharm Sci 1997; 86:1127-1131.
71. Moraes-Souza H, Pianetti GM, Barretto OCP, et al. Aminoquinoline WR6026 as a feasible substitute for gentian violet in chagas' disease prophylaxis in preserved blood for transfusional purpose. Rev Soc Bras Med Trop 2002; 35:563-569
72. Chirai E, Oliveira AB, Prado MAF, et al. Potential use of WR6026 as prophylaxis against transfusion-transmitted American Trypanosomiasis. Antimicrob Agents Chemother 1996; 40:613-615.
73. Augusto O, Alves MJ, Colli W, et al. Primaquine can mediate hydroxyl radical generation by Trypanosoma cruzi extracts. Biochem Biophys Res Commun 1986; 135:1029-1034.
74. Krause PJ. Babesiosis diagnosis and treatment. Vector Borne Zoonotic Dis 2003; 3:45-51.
75. Mitrovic S, Kranjcic-Zec I, Arsic-Arsenijevic V, et al. Human babesiosis-recent discoveries. Med Pregl 2004; 57:349-353.
76. Marley SE, Eberhard ML, Steurer FJ, et al. Evaluation of selected antiprotozoal drugs in the Babesia microti-hamster model. Antimicrob Agents Chemother 1997; 41:91-94.
77. Penzhorn BL, Lewis BD, Lopez-Rebollar, et al. Screening of drugs for efficacy against Babesia felis in experimentally infected birds. J S Afr Vet Assoc 2000; 71:530-557.
78. Nagai A, Yokoyama N, Matsuo T, et al. Growth-inhibitory effect of artesunate, pyrimethamine and pamaquine against Babesia equi and Babesia caballi in in vitro cultures. Antimicrob Agents Chemother 2003; 47:800-803.
79. Dalloul RA, Lillehoj HS. Poultry coccidiosis: recent advancements in control measures and vaccine development. Exp Rev Vaccines 2006; 5:143-163.
80. Matsuno T, Hariguchi F, Okamoto T. Anticoccidial activity of 8-aminoquinolines, pamaquine, primaquine and several molecular complexes and salts of pamaquine, against Eimeria tenella, E necatrix, E acervuliana, E maxima and E brunette in battery experiments. J Vet Med Sci 1991; 53:13-17.
81. Armer R, Barlow JS, Chopra N, et al. 8-Aminoquinolines as anticoccidials III. Bioorg Med Chem Lett 1999; 9:2425-2430.
82. Feldman C. Pneumonia associated with HIV infection. Curr Opin Infect Dis 2005; 18:165-170.
83. Queener SF, Dean RA, Bartlett MS, et al. Efficacy of intermittent dosage of 8-aminoquinoline for therapy or prophylaxis of Pneumocystis carinii. J Infect Dis 1992; 165:764-768.
84. Barlett MS, Queener SF, Tidwell RR, et al. 8-Aminoquinolines from Walter Reed Army Institute for Research for treatment and prophylaxis of Pneumocystis pneumonia in rat models. Antimicrob Agents Chemother 1991; 35:277-282.
85. Queener SF, Bartlett MS, Nasr M, et al. 8-aminoquinolines effective against Pneumocystis carinii in vitro and in vivo. Antimicrob Agents Chemother 1993; 37:2166-2172.
86. Goodwin TE, Boylan CJ, Current WL, et al. Enhanced Pneumocystis carinii activity of new primaquine analogs. Bioorg Med Chem Lett 2000; 10:2205-2208.
87. Goheen MP, Bartlett MS, Queener SF, et al. The effect of primaquine on the ultrastructural morphology of Pneumocystis carinii. J Protozool 1991; 38:164S-165S.
88. Goheen MP, Bartlett MS, Shaw MM, et al. Effects of 8-aminoquinolines on the ultrastructural morphology of Pneumocystis carinii. Int J Exp Pathol 1993; 74:379-387.
89. Federsel HJ. Asymmetry on large scale: the roadmap to stereoselective processes. Nat Rev Drug Discov 2005; 4:685-697.
90. Krudsood S, Wilairatana P, Tangpukdee N, et al. Safety and tolerability of elubaquine (bulaquine, CDRI 80/53) for treatment of Plasmidium vivax malaria in Thailand. Korean J Parasitol 2006; 44:221-228. The paper reports that bulaquine is safer than primaquine in patients with glucose 6-phosphate dehydrogenase deficiency.